<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821496</url>
  </required_header>
  <id_info>
    <org_study_id>OB-108</org_study_id>
    <nct_id>NCT00821496</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects</brief_title>
  <official_title>A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is desgigned to look at the effect of multiple dosing administration of VI-0521 on
      Oral Contraceptive medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine if multiple oral doses of VI-0521 would alter the
      pharmacokinetics of an oral contraceptive in healthy female subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK of the Oral contraceptive agent</measure>
    <time_frame>31 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>saftey and tolerability of multiple dose adminstration of VI-0521 in healthy female subjects</measure>
    <time_frame>31</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinyl estradiol, norethindrone, VI-0521</intervention_name>
    <description>Oral contraceptive</description>
    <arm_group_label>Oral Contraceptive</arm_group_label>
    <other_name>VI-0521, Ortho-Novum 1/35-28</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females, 19 - 64 years of age (inclusive), who are non-pregnant, not planning
             pregnancy and non-breast-feeding.

          2. If females of child-bearing potential, be using adequate contraception, defined as
             double barrier methods, single barrier plus tubal ligation.

          3. A body weight of at least 50 kg and a body mass index (BMI) between 27 and 35 kg/m2,
             inclusive.

          4. Medically healthy, with clinically insignificant screening results.

          5. Subjects are able to communicate with the investigator, and to understand and comply
             with all requirements of study participation.

          6. Voluntarily consent to participate in the study.

        Exclusion Criteria:

          1. A history or presence of significant cardiovascular, neurological, hematological,
             psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal
             disease or other condition known to interfere with the absorption, distribution,
             metabolism, or excretion of drugs or place the subjects at increased risk as
             determined by the investigator.

          2. Any clinically significant laboratory abnormalities as judged by the investigator.

          3. Any history of glaucoma, increased intraocular pressure, or medications to treat
             increased intraocular pressure.

          4. Presence of cholelithiasis or cholecystitis within the last 6 months that has not been
             surgically treated with cholecystectomy.

          5. Any history of a cardiovascular or cerebrovascular event.

          6. Systolic blood pressure &gt; 150 mm Hg or diastolic blood pressure &gt; 95 mm Hg at
             screening or at check-in on Day -1.

          7. Positive urine drug test, serum cotinine test, pregnancy test and/or positive urine
             alcohol test at screening or check in Day -1.

          8. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HBsAg), or hepatitis C antibodies (HCV) at screening.

          9. Any history or presence of alcoholism or drug or substance abuse as defined by the
             investigator.

         10. Any active malignancy except basal cell carcinoma.

         11. A history of breast cancer.

         12. Any history of bipolar disorder or psychosis, history of psychiatric hospitalization,
             greater than one lifetime episode of major depression.

         13. A history of intolerance to oral contraceptives.

         14. A history of hypersensitivity or idiosyncratic reaction to the active drugs, compounds
             related to the study drugs or to any excipients present in the VI-0521 capsule.

         15. Use of any prescription or over-the-counter (OTC) medication, including herbal
             products, within the 14 days prior to Day -1. Up to 2 g per day of acetaminophen is
             allowed at the discretion of the Investigator.

         16. Use of any drug known to have a significance in inhibiting or inducing liver enzymes
             involved in drug metabolism [CYP P450]) within 30 days prior to Day -1.

         17. Blood donation or significant blood loss within 56 days prior to Day -1.

         18. Plasma donation within 7 days prior to Day -1.

         19. Any use of tobacco or nicotine products within 3 months prior to Day -1.

         20. Any history of celiac diseases, food allergies, and those on vegetarian or other diets
             incompatible with study objectives.

         21. Any subject who received an investigational drug within 30 days or six half-lives,
             whichever is longer, prior to dosing in this study.

         22. Clinical judgment by the investigator that the subject should not participate in the
             study.

         23. Involvement in the planning and conduct of the study.

         24. Any subject who has participated in a previous clinical trial with VI-0521.

         25. Subjects with any condition possibly affecting drug absorption.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyin Yee</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Sharples, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>November 30, 2009</last_update_submitted>
  <last_update_submitted_qc>November 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <keyword>Multiple dose administration</keyword>
  <keyword>Oral Contraceptives</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

